SkyePharma/Astralis Psoraxine enters Phase I

SkyePharma says that US partner Astralis has initiated a Phase I clinical trial in the USA for Psoraxine, a novel injectable protein-based treatment for moderate psoriasis. A first-generation Psoraxine has been studied in Venezuela, where nearly 3,000 patients participated in an open-label clinical trial, with the vast majority showing a positive response with few side effects. The US study, double-blinded and placebo-controlled in design, is being conducted by William Abramovits, professor of dermatology at the Baylor University Medical Center, Dallas, USA.